Compare New York Times Co (NYT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Organon & Co. Common Stock — how do they compare? New York Times Co trades at $67.58 (market cap $10.83B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: New York Times Co is far larger — about 3× Organon & Co. Common Stock's market cap, and New York Times Co pays the higher dividend (1.37%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 82 Days and Organon & Co. Common Stock for 0 Days on average.
| NYT | OGN | |
|---|---|---|
Market Cap | $10.83B | $3.61B |
Volume | 1,004,378 | 1,808,049 |
Sector | Media | Health |
52-Week High | $85.86 | $13.81 |
52-Week Low | $54.86 | $5.70 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $10.22B | $11.03B |
Dividend Yield | 1.37% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.88, up 1.21% today, with a bearish technical signal but strong fundamental performance. Revenue grew to $2.82B in 2025 with a net income margin of 12.17%, and the company has beaten EPS estimates for three consecutive quarters. A recent shareholder lawsuit alleging bias in reporting and the ongoing AI copyright case with OpenAI are key news items.
The outlook is mixed: solid earnings growth and a consensus price target of $81.50 suggest upside, but legal risks and a bearish technical picture near-term pose challenges. The stock offers a dividend yield supported by positive cash flow, yet investor sentiment is cautious amid litigation concerns.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
